What it is
Tesamorelin is a synthetic peptide. A peptide is a short chain of amino acids, the building blocks of proteins. It is a close copy of growth hormone-releasing hormone (GHRH), a natural hormone that tells the pituitary gland at the base of the brain to release growth hormone. The FDA label describes tesamorelin as the full 44-amino-acid human hormone with a small chemical group (a hexenoyl group) attached to the first amino acid. The label uses the older name for the hormone, growth hormone-releasing factor (GRF).
More on what it is and where it came from
In the United States it is a prescription medicine made by Theratechnologies and sold as Egrifta. The FDA first approved it on November 10, 2010. The current labels give one approved use: to reduce excess abdominal fat in adults with HIV and lipodystrophy (a change in where the body stores fat, seen in some people treated for HIV). Two newer versions followed: a more concentrated version whose label is dated November 2018 (now called Egrifta SV), and Egrifta WR, a new formulation in a multiple-dose vial, approved on March 25, 2025.
The label sets three limits on that use. It says long-term cardiovascular safety has not been established. It says the medicine is not indicated for weight loss management because it has a weight-neutral effect. And it says there are no data showing it helps people keep taking their HIV medicines. Tesamorelin is also sold online as an unapproved powder labeled for research use. Nothing on this page is advice about using any form of tesamorelin.
Human GHRH is a natural 44-amino-acid hormone (listed in the UniProt protein database as somatoliberin). Tesamorelin is a modified copy of it developed by the company Theratechnologies under the code name TH9507. The first large trial was published in the New England Journal of Medicine in December 2007, a second phase 3 trial and a pooled analysis followed in 2010, and the FDA approved it as Egrifta on November 10, 2010. On March 23, 2020 the FDA reclassified it, along with other protein medicines such as insulin and growth hormone, from a drug approval to a biologics license.
How it is thought to work
According to the FDA label, tesamorelin binds to and switches on the same receptors as the body's own GHRH, with similar strength in laboratory tests. This prompts the pituitary gland to release growth hormone. Growth hormone in turn raises blood levels of IGF-1 (insulin-like growth factor 1, a growth-promoting hormone) and a related carrier protein, IGFBP-3. The label notes that some effects of growth hormone are carried out through IGF-1.
More on how it works
In the phase 3 trials, people on tesamorelin lost visceral fat (fat stored deep in the belly around the organs) while the fat just under the skin did not change significantly. Lean body mass rose by a little over 1 kg. The label reports no clinically significant changes in other pituitary hormones that were measured (TSH, LH, ACTH and prolactin).
Tesamorelin itself does not stay in the blood for long. The labels give an elimination half-life (the time for the blood level to fall by half) of about 8 to 11 minutes in healthy volunteers, depending on the formulation. Why raising growth hormone reduces deep belly fat in particular is not explained in the label sections read for this page.
What is established in people
In adults with HIV and excess abdominal fat, two randomized, placebo-controlled phase 3 trials of about 400 people each showed that tesamorelin reduced deep belly fat by roughly 14% to 18% over 26 weeks, without changing body weight. The fat returned within 26 weeks in people switched to placebo. Smaller trials found less liver fat in people with HIV, and one-year effects on belly fat in obese adults without HIV, but those are not approved uses. No trial has shown fewer heart attacks, strokes or deaths, the label says long-term cardiovascular safety has not been established, and two small trials on thinking and memory gave conflicting results.
What the studies found
14 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment
At what the authors called a low dose, tesamorelin did not significantly change any main measure compared with placebo.
Full finding, who was studied, and limits
Who: 24 adults aged 55 to 85 were enrolled and 22 analysed: 10 given tesamorelin and 12 given placebo for 10 weeks, double-blind. On screening, 17 had normal thinking and only 5 had mild cognitive impairment. Run at the University of Texas Medical Branch, Galveston (registration NCT02553603), funded by a US National Institutes of Health translational science award and a private endowment; Theratechnologies, the maker, donated the tesamorelin.
At what the authors called a low dose, tesamorelin did not significantly change any main measure compared with placebo. IGF-1 (the hormone that growth hormone raises) did not differ between groups, and there were no significant group differences in body composition, fatigue, sleep, a walking test, blood sugar handling, thinking test scores (the total score improved by about 1.5 points in both groups) or brain scans. When the researchers then ran machine-learning models on the scan and test data, they picked out possible treatment-related differences in a few brain areas linked to thinking, including the right anterior cingulate.
Read with care: A small pilot, mostly in people with normal thinking, so it says little about mild cognitive impairment. Ten weeks only, and the low dose did not raise IGF-1, so it is unclear whether the drug had its usual effect on the body. The brain-area differences came from exploratory machine-learning analysis after the main comparisons found nothing; the authors call the results hypothesis-generating. The trial finished in 2019 and was published in 2026. Unlike the larger 2012 trial above, which found a modest benefit at 20 weeks, this one found none.
- Human trial2026
Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS
The lab found five breakdown products (metabolites) of tesamorelin not reported before.
Full finding, who was studied, and limits
Who: 6 healthy volunteers given tesamorelin (Egrifta) for 10 days in a row, meant to mimic doping, with urine and blood collected afterwards. Tesamorelin was also left in fresh human blood serum in the lab to see how it breaks down. A drug-testing study with no comparison group, not a treatment trial. Run by the doping control laboratory of Ghent University, Belgium, and the Sports Medicine Research and Testing Laboratory in Salt Lake City, USA.
The lab found five breakdown products (metabolites) of tesamorelin not reported before. Even with a test about 70 times more sensitive than WADA's minimum requirement, tesamorelin use could not be detected in urine collected after use. In blood, metabolites were found in all six volunteers, but only for up to 2 hours after it was given; intact tesamorelin was found in just two volunteers, for up to 30 minutes. The authors concluded that tesamorelin has a very short detection window and that testing should look for metabolites in blood rather than the drug in urine.
Read with care: Only six people, all healthy volunteers. This is a study of drug testing, not of any health effect, and the abstract reports no benefits or side effects. Only the abstract was read, so details such as the volunteers' age and sex are not given here. The result describes testing methods at the time of the study; anti-doping laboratories may change their methods.
- Human trial2026
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (NCT03150511)
No findings yet.
Full finding, who was studied, and limits
Who: A planned 36 adults whose ulnar nerve (a main nerve to the hand) was cut at the wrist and repaired by surgery, randomly assigned to tesamorelin or to no treatment (18 each) and followed for 12 months. Phase 2. There is no placebo; the description says the people assessing recovery and the statistician do not know who was treated. Run by Johns Hopkins University with US Department of Defense funding; it began in June 2018.
No findings yet. The trial is testing whether tesamorelin, by raising the body's own growth hormone, speeds and improves recovery of movement and feeling after nerve repair; the registry says growth hormone improved nerve regrowth and recovery in animal studies. The main measure is pinch strength at 12 months; others include hand-function questionnaires, nerve conduction tests and standard grades of muscle and sensory recovery. In the record updated on 9 November 2026 it was still recruiting, with completion estimated for December 2027 and no results posted. No paper from this trial was found on PubMed.
Read with care: A registration, not a result: nothing is yet known about whether tesamorelin helps nerve recovery in people. The rationale rests on animal studies of growth hormone, not on tesamorelin in people with nerve injury. The trial is small, has been running since 2018, and its comparison group gets no treatment rather than a placebo. It is listed here so that a reader who hears of it knows its status.
- Human trial2025
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Thinking test scores did not differ significantly between the tesamorelin group and the usual-care group (P = 0.673).
Full finding, who was studied, and limits
Who: 73 people with well-controlled HIV, abdominal obesity and thinking problems, randomly assigned 3 to 2 to tesamorelin or to usual care for 6 months. Phase 2, open-label (everyone knew who was treated).
Thinking test scores did not differ significantly between the tesamorelin group and the usual-care group (P = 0.673). Waist size fell more with tesamorelin (a difference of 2.7 cm). IGF-1 rose, but the rise was not linked to changes in thinking scores. The authors found no clear benefit of short-term belly fat reduction for thinking problems.
Read with care: This is the result that tempers the earlier cognition finding. The trial was small, had no placebo group, and the authors said it may have been too small to detect an effect. Six months long.
- Human trial2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Liver fat fell more on tesamorelin: an absolute difference of 4.1 percentage points against placebo, or 37% in relative terms.
Full finding, who was studied, and limits
Who: 61 adults with HIV and fatty liver (liver fat of 5% or more on a scan), at two US centres, randomly assigned to tesamorelin or placebo for 12 months. About a third had the more serious inflamed form (NASH) and 43% had some liver scarring (fibrosis) at the start.
Liver fat fell more on tesamorelin: an absolute difference of 4.1 percentage points against placebo, or 37% in relative terms. Liver fat dropped below 5% in 35% of people on tesamorelin and 4% on placebo. In people with repeat liver biopsies, scarring got worse in 2 people on tesamorelin (10.5%) and 9 on placebo (37.5%). The overall liver disease activity score did not differ significantly between groups. Fasting blood sugar and HbA1c (a three-month average of blood sugar) did not differ at 12 months. More people on tesamorelin had injection-site complaints. Two people on tesamorelin stopped because of high blood sugar.
Read with care: Small. The scarring result rests on 11 people whose scarring got worse and was not the main outcome. The authors said longer studies are needed to learn the effect on the liver itself. Fatty liver disease is not an FDA-approved use. Funded by the US National Institutes of Health; the maker supplied the medicine at reduced cost.
- Human trial2017
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
There were no significant differences between groups in the insulin response to a sugar drink, fasting blood sugar, HbA1c or overall diabetes control at 12 weeks.
Full finding, who was studied, and limits
Who: 53 adults with type 2 diabetes, randomly assigned to placebo or one of two tesamorelin dose groups for 12 weeks.
There were no significant differences between groups in the insulin response to a sugar drink, fasting blood sugar, HbA1c or overall diabetes control at 12 weeks. No one left the study because of loss of diabetes control. Total cholesterol and non-HDL cholesterol fell in the higher dose group.
Read with care: Small and only 12 weeks long, so it cannot rule out an effect on blood sugar over a longer time. The FDA label, drawing on the larger HIV trials, reports that more people on tesamorelin than on placebo crossed the HbA1c threshold for diabetes.
- Human trial2014
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Visceral fat fell by 34 square centimetres on tesamorelin and rose by 8 on placebo.
Full finding, who was studied, and limits
Who: 50 adults with HIV on antiretroviral treatment with abdominal fat accumulation, at one hospital in Boston. 28 were assigned to tesamorelin and 22 to placebo for 6 months. Double-blind.
Visceral fat fell by 34 square centimetres on tesamorelin and rose by 8 on placebo. Liver fat fell modestly: the middle (median) change was -2.0 percentage points on tesamorelin against +0.9 on placebo. Fasting blood sugar was higher on tesamorelin at 2 weeks (up 9 points on the standard US lab scale, against 2 on placebo) but the difference was no longer significant at 6 months.
Read with care: Small, single-centre and described by its authors as preliminary. The authors said more study was needed to learn whether the liver fat change matters clinically. It shows a short-term rise in blood sugar soon after starting.
- Human trial2012
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial
Visceral fat fell by 16 square centimetres on tesamorelin and rose by 19 on placebo.
Full finding, who was studied, and limits
Who: 60 adults without HIV who had abdominal obesity and low growth hormone release, randomly assigned to tesamorelin or placebo for 12 months. Double-blind.
Visceral fat fell by 16 square centimetres on tesamorelin and rose by 19 on placebo. Fat under the skin did not change significantly. Triglycerides and CRP (a blood marker of inflammation) improved. The wall of the neck artery, measured by ultrasound, was 0.04 mm thinner relative to placebo. IGF-1 rose. Fasting blood sugar, blood sugar after a sugar drink, and HbA1c did not change. No serious side effects were reported.
Read with care: Small, and in a selected group (obese people with reduced growth hormone release), so it does not apply to people with obesity in general. Artery wall thickness is a stand-in measure, not a count of heart attacks or strokes. This is not an FDA-approved use, and the label says tesamorelin is not for weight loss.
Journal of Clinical Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Human trial2012
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Thinking test scores were modestly better on tesamorelin than placebo overall (P = 0.03).
Full finding, who was studied, and limits
Who: 152 adults aged 55 to 87 (average 68), 66 of them with mild cognitive impairment (memory and thinking problems short of dementia) and the rest healthy. Randomly assigned to tesamorelin or placebo for 20 weeks. Double-blind. 137 completed.
Thinking test scores were modestly better on tesamorelin than placebo overall (P = 0.03). The clearest effect was on executive function (planning and attention tasks); verbal memory showed only a trend. IGF-1 rose by 117% and stayed within the normal range. Body fat fell by 7.4%. Fasting insulin rose by 35% in the group with mild cognitive impairment. Side effects, described as mild, were reported by 68% on tesamorelin and 36% on placebo.
Read with care: Twenty weeks long, with test scores as the outcome, not daily function or progression to dementia. The authors called for longer trials. A later trial in people with HIV found no significant benefit for thinking (see the 2025 entry). This is not an FDA-approved use.
Archives of Neurology (NCT00257712) · pubmed.ncbi.nlm.nih.gov
- Human trial2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
In the first 6 months, visceral fat fell by 10.9% (21 square centimetres on the scan) on tesamorelin, against 0.6% (1 square centimetre) on placebo.
Full finding, who was studied, and limits
Who: 404 adults with HIV and excess abdominal fat, randomly assigned 2 to 1 to tesamorelin or placebo for 6 months, with patients and investigators blinded. A 6-month extension followed, in which people on tesamorelin were randomly assigned again to continue or to switch to placebo.
In the first 6 months, visceral fat fell by 10.9% (21 square centimetres on the scan) on tesamorelin, against 0.6% (1 square centimetre) on placebo. Trunk fat, waist size and distress about belly appearance also improved. Fat in the limbs and fat under the skin of the abdomen did not change. Those who continued for 12 months had lost about 18% of their visceral fat. Those switched to placebo lost the earlier gain: the FDA label reports their visceral fat rose by 16% between week 26 and week 52.
Read with care: This second trial showed a smaller effect than the first. The abstract does not report triglyceride or cholesterol results. One year in total. Paid for by the maker. The FDA label gives group sizes of 270 and 126, which do not add up to the 404 randomized; the reason was not confirmed.
- Human trial2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
At 26 weeks, visceral fat fell by 24 square centimetres on tesamorelin and rose by 2 on placebo, a difference of 15.4%.
Full finding, who was studied, and limits
Who: 806 adults with HIV on antiretroviral treatment with excess abdominal fat, pooled from the two phase 3 trials: 543 on tesamorelin and 263 on placebo for 26 weeks, then a 26-week extension.
At 26 weeks, visceral fat fell by 24 square centimetres on tesamorelin and rose by 2 on placebo, a difference of 15.4%. Fat under the skin of the abdomen did not change significantly (difference of 0.6%). Triglycerides and the cholesterol-to-HDL ratio improved. IGF-1 rose by 108 ng/mL on tesamorelin and fell by 7 on placebo. In people who stayed on tesamorelin for 52 weeks, visceral fat was down 17.5% and waist size was down 3.4 cm. The authors reported no clinically meaningful differences in blood sugar measures.
Read with care: A pooled re-analysis of the two maker-funded trials above, not new patients. The outcomes are scans, blood fats and body image scores. Neither trial was designed to show fewer heart attacks, strokes or deaths, and the FDA label says long-term cardiovascular safety has not been established.
Journal of Clinical Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Human trial2008
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
In those who stayed on tesamorelin, visceral fat was down 18% and triglycerides were down 51 points on the same lab scale after 52 weeks.
Full finding, who was studied, and limits
Who: The same people as the 2007 trial, followed for a further 26 weeks (52 weeks in total). At week 26, those on tesamorelin were randomly assigned again: 154 continued and 50 were switched to placebo. The 111 who had been on placebo were switched to tesamorelin.
In those who stayed on tesamorelin, visceral fat was down 18% and triglycerides were down 51 points on the same lab scale after 52 weeks. Changes in blood sugar were not clinically significant. In those switched to placebo, the fat returned: the FDA label reports that their visceral fat rose by 22% between week 26 and week 52, against no change in those who continued. The authors concluded that the effect on visceral fat did not last beyond the treatment period.
Read with care: An extension study, so the groups at week 52 are smaller and made up of people who tolerated the first 26 weeks. One year in total. Paid for by the maker.
- Human trial2007
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Visceral fat (deep belly fat, measured by CT scan) fell by 15.2% on tesamorelin and rose by 5.0% on placebo.
Full finding, who was studied, and limits
Who: 412 adults with HIV and excess abdominal fat (86% men), randomly assigned to tesamorelin or placebo for 26 weeks. The FDA label gives the split as 273 on tesamorelin and 137 on placebo, and describes the trial as multicenter, randomized, double-blind and placebo-controlled.
Visceral fat (deep belly fat, measured by CT scan) fell by 15.2% on tesamorelin and rose by 5.0% on placebo. Triglycerides (a blood fat) fell by 50 points on tesamorelin and rose by 9 on placebo, on the standard US lab scale. The ratio of total cholesterol to HDL cholesterol also improved. IGF-1 rose by 81.0% on tesamorelin and fell by 5.0% on placebo. Blood sugar measures did not differ significantly between groups. More people on tesamorelin left the trial because of side effects.
Read with care: Six months long. It measured fat on scans and blood tests, not heart attacks, strokes or deaths. Paid for by the maker. The FDA label reports slightly different figures for the same trial (visceral fat down 18% on tesamorelin, up 2% on placebo), because it uses a different analysis.
New England Journal of Medicine (NCT00123253) · pubmed.ncbi.nlm.nih.gov
- Review2026
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Across the five trials, tesamorelin reduced visceral fat by about 28 square centimetres and liver fat by about 4.3 percentage points, and raised lean body mass by about 1.4 kg, compared with placebo.
Full finding, who was studied, and limits
Who: A pooled analysis of five randomized trials comparing tesamorelin with placebo in adults with HIV-associated lipodystrophy.
Across the five trials, tesamorelin reduced visceral fat by about 28 square centimetres and liver fat by about 4.3 percentage points, and raised lean body mass by about 1.4 kg, compared with placebo. Waist size fell by about 1.6 cm. There was no significant change in fat under the skin, in body mass index, or in CD4 cell counts (a measure of immune health in HIV). Joint pain, muscle pain, tingling and injection-site reactions were the side effects noted.
Read with care: It pools the same small set of trials described above, so it adds no new patients. The abstract does not give the total number of participants, how much the trials differed from one another, or any limitations. It confirms no change in body mass index, in line with the label's statement that tesamorelin does not change weight.
Obesity Research and Clinical Practice · pubmed.ncbi.nlm.nih.gov
Safety findings
- Who must not use it, according to the label (contraindications): people whose pituitary system has been disrupted (for example by pituitary surgery or a pituitary tumor, head irradiation or head trauma), people with active cancer, people with a known allergy to tesamorelin or the other ingredients, and pregnant women. Source: dailymed.nlm.nih.gov
- IGF-1 rise: tesamorelin raises IGF-1, a growth factor. In the phase 3 trials, 47% of people on tesamorelin had IGF-1 more than 2 standard deviations above average at 26 weeks, and 36% were more than 3 above. At 52 weeks the figures were 34% and 23%. The label says the effects of prolonged IGF-1 elevation are unknown, tells prescribers to monitor IGF-1, and carries a warning on increased risk of neoplasms (new growths, including cancers). It also says lifetime cancer studies in rodents have not been done. Source: dailymed.nlm.nih.gov
- Blood sugar: the label warns of glucose intolerance and diabetes. In the phase 3 trials, 5% of people on tesamorelin and 1% on placebo developed an HbA1c of 6.5% or higher (the level used to diagnose diabetes) by week 26, a hazard ratio of 3.3 (confidence interval 1.4 to 9.6). Average HbA1c at the start was 5.3% in both groups. Source: dailymed.nlm.nih.gov
- Most common side effects in the first 26 weeks of the phase 3 trials (tesamorelin against placebo, label table): joint pain 13% against 11%; pain in arms or legs 6% against 5%; muscle pain 6% against 2%; swelling of the hands or feet 6% against 2%; tingling 5% against 2%; numbness 4% against 2%; rash 4% against 2%; vomiting 3% against 0%. The label groups swelling, joint pain and carpal tunnel syndrome as signs of fluid retention and says they were usually temporary or went away after stopping. Source: dailymed.nlm.nih.gov
4 more safety findings
- Injection-site reactions (redness, itching, pain, irritation, bruising) were common. The label's warning section gives 25% on tesamorelin against 14% on placebo in the first 26 weeks; its side-effect table lists 17% against 6%. The text read does not explain the difference between the two sets of figures. Allergic-type reactions (itching, redness, flushing, hives, rash) occurred in 4% of people on tesamorelin. Source: dailymed.nlm.nih.gov
- Antibodies: about half of people in the trials developed antibodies against tesamorelin (50% at 26 weeks, 47% at 52 weeks). In about 60% of those people the antibodies also recognised the body's own GHRH. Antibodies able to block activity in laboratory tests were found at week 52 in 10% (against tesamorelin) and 5% (against human GHRH). Source: dailymed.nlm.nih.gov
- Pregnancy: the label says changing deep belly fat offers no benefit in pregnancy and could harm the fetus. In rats, tesamorelin given during pregnancy caused hydrocephaly (fluid build-up in the brain) in offspring at about 2 to 4 times the human exposure. The label also carries a class warning that growth hormone given in large amounts has been linked to more deaths in people with acute critical illness. Source: dailymed.nlm.nih.gov
- Unapproved products: there are no human safety studies of tesamorelin sold for 'research use'. In warning letters dated August 24, 2026 the FDA told online sellers that their tesamorelin products were unapproved new drugs, and said that injectable products can pose risks of serious harm because they bypass the body's defenses against toxins and germs. Source: fda.gov
Rules and status
FDA-approved prescription medicine (Egrifta SV and Egrifta WR, Theratechnologies), licensed as a biological product. The only approved use is to reduce excess abdominal fat in adults with HIV and lipodystrophy. Tesamorelin sold online for 'research use' is an unapproved new drug in the FDA's view.
The full history, with dates
Approval: the FDA approved Egrifta on November 10, 2010 (application 022505, Theratechnologies). A label dated November 2018 covers a more concentrated formulation, later sold as Egrifta SV; the exact approval day of that change was not confirmed. On March 25, 2025 the FDA approved Egrifta WR, described in the approval letter as a new formulation and a new multiple-dose presentation. The Egrifta WR label on DailyMed (text revised March 2025, page updated July 29, 2026) gives the indication as reducing excess abdominal fat in adult patients with HIV and lipodystrophy. Its limitations of use read: 'Long-term cardiovascular safety of EGRIFTA WR has not been established'; it 'is not indicated for weight loss management as it has a weight neutral effect'; and there are no data showing improved compliance with antiretroviral therapy. The label says the two current versions cannot be substituted for one another. Biologic status: tesamorelin acetate is on the FDA's list of approved drug applications for biological products that were deemed to be biologics licenses on March 23, 2020, and the 2025 approval letter treats it as a biologics license under section 351 of the Public Health Service Act. Compounding: the FDA states that 'Biological products are not eligible for the exemptions for compounded drugs' under sections 503A and 503B (FDA questions-and-answers page, current as of September 16, 2025), and its 2020 notice to compounders said the products that became biologics on that date would no longer be eligible. Tesamorelin does not appear in any category of the FDA's list of bulk substances nominated for 503A compounding (updated May 14, 2026), and it is not on the FDA's page of bulk substances that may present significant safety risks (current as of April 22, 2026). No FDA document was found that applies the biologics rule to tesamorelin by name; the conclusion rests on the FDA's general rule plus its own list. As a record of past practice, an FDA warning letter of April 1, 2020 to a compounding pharmacy noted that firm's recall of compounded tesamorelin made in 2018 because of a wrong beyond-use date on the label. HHS draft policy: on October 30, 2026 HHS published a notice in the Federal Register of a draft, non-binding enforcement-discretion policy for 503A compounding of certain peptides. The notice itself names no peptides; Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of November 15, 2026) names exactly six: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Tesamorelin is not among them. Unapproved products: in warning letters dated August 24, 2026, the FDA told at least two online sellers (Peak Performance Peptides and NuScience Peptides LLC) that their tesamorelin products were unapproved new drugs, and that labels such as 'research use only' and 'not for human consumption' did not change this because the websites showed the products were intended for human use.
Source: dailymed.nlm.nih.gov (source dated 2026-07-29)
In sport: Prohibited at all times (in and out of competition). Tesamorelin is named in class S2, section S2.2.4, growth hormone releasing factors: 'growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)'. The wording is the same in the 2026 List (in force from January 1, 2026) and the 2027 List (published September 21, 2026, in force from January 1, 2027). The 2026 List states that all substances in class S2 are non-Specified Substances. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| Tesamorelin is a weight-loss drug. | The FDA label says the opposite: it is not indicated for weight loss management because it has a weight-neutral effect. In the trials it reduced deep belly fat, while body weight did not clearly change. A 2026 pooled analysis of five trials found no significant change in body mass index. Source: dailymed.nlm.nih.gov |
| The belly fat stays off after stopping. | It did not in the trials. People switched from tesamorelin to placebo at week 26 regained 16% to 22% of their visceral fat by week 52, according to the FDA label. The authors of the extension study concluded the effect did not last beyond the treatment period. Source: pubmed.ncbi.nlm.nih.gov |
| It burns fat all over the body. | The effect in trials was on visceral fat, the fat deep in the belly. In the pooled phase 3 analysis, fat under the skin of the abdomen did not change significantly, and the second phase 3 trial found no change in limb fat. Source: pubmed.ncbi.nlm.nih.gov |
| It protects the heart. | Not shown. The trials measured scans and blood fats, not heart attacks or strokes, and the FDA label states that long-term cardiovascular safety has not been established. One small trial in obese adults without HIV found a slightly thinner neck artery wall on ultrasound, which is a stand-in measure only. Source: dailymed.nlm.nih.gov |
| It improves memory and thinking. | Mixed, from two small trials. A 20-week trial of 152 older adults found modestly better test scores, mainly in executive function. A 2025 trial of 73 people with HIV found no significant difference from usual care. It is not approved for this. Source: pubmed.ncbi.nlm.nih.gov |
| It has no effect on blood sugar. | The trial reports describe no clinically meaningful change in average blood sugar. But the FDA label reports that 5% of people on tesamorelin and 1% on placebo reached the HbA1c level used to diagnose diabetes within 26 weeks, and it carries a warning on glucose intolerance and diabetes. Source: dailymed.nlm.nih.gov |
| Research-grade tesamorelin sold online is the same thing as Egrifta. | The FDA treats these products as unapproved new drugs and sent warning letters to sellers in August 2026. None of the trials on this page tested them. The approved medicine is a licensed biological product made under FDA oversight. Source: fda.gov |
| It is allowed in sport because it is a prescription medicine. | It is prohibited at all times. The 2026 WADA Prohibited List names tesamorelin as an example of a growth hormone-releasing hormone analogue in class S2. Source: wada-ama.org |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match tesamorelin's expected molecular weight of about 5136 Da (FDA label: 5135.9 Da for the free base; PubChem monoisotopic mass: 5132.72 Da). Tesamorelin is human GHRH plus a hexenoyl group, so a peptide missing that group would show a lower mass. A report with a different mass, or with no mass data, does not confirm identity.
- Purity by HPLC (a method that separates a sample into its components), with the actual chromatogram shown, the purity percentage, and any impurity peaks listed. At 44 amino acids this is a long peptide to build, so shortened or mis-built chains are a realistic impurity.
- Content: the measured amount of peptide in the vial compared with the amount on the label. Tesamorelin is supplied as an acetate salt (the FDA label describes about 7 acetic acid units per molecule), so a report should make clear whether the stated amount is peptide alone or peptide plus salt.
- Traceability: the report should name the testing laboratory, the lot or batch number and the test date, and the lot number should match the product.
- What a lab report cannot do: a certificate of analysis does not make a product FDA-approved, and it does not show the product is sterile or free of bacterial toxins unless those tests were run and reported. The FDA has warned that injectable products can cause serious harm because they bypass the body's defenses.
What is not known
- Whether reducing deep belly fat with tesamorelin lowers the rate of heart attacks, strokes or deaths. No trial has tested this, and the label says long-term cardiovascular safety has not been established.
- The long-term effect of keeping IGF-1 raised, including any effect on cancer risk. The label says this is unknown, and lifetime cancer studies in rodents have not been done.
- Whether the fall in liver fat seen in small HIV trials leads to healthier livers over time. The authors of the 2019 trial said longer studies are needed.
- Whether it helps thinking or memory. Two small trials disagree.
- Whether results from people with HIV and lipodystrophy apply to anyone else. Trials outside HIV were small (60 and 53 people) and are not approved uses.
- The label gives two different figures for injection-site reactions (25% against 14% in the warnings; 17% against 6% in the table). The reason was not found in the text read.
- The exact approval date of the more concentrated formulation (Egrifta SV). Its label is dated November 2018, but the FDA's approval-history table shows no action date for that supplement.
- No FDA document was found that says in so many words that tesamorelin cannot be compounded. That conclusion combines the FDA's general statement about biological products with tesamorelin's presence on the FDA's list of products that became biologics in 2020.
- The published papers and the FDA label give slightly different numbers for the same trials (for example, visceral fat change in the first trial: -15.2% against +5.0% in the paper, -18% against +2% in the label). They appear to use different analysis methods.
Sources
All 34 sources
- PubChem: Tesamorelin (CID 16137828). pubchem.ncbi.nlm.nih.gov
- UniProt P01286: Somatoliberin (human GHRH). uniprot.org
- DailyMed: Egrifta WR prescribing information (text revised 3/2025; page updated July 29, 2026). dailymed.nlm.nih.gov
- DailyMed: Egrifta SV prescribing information (page updated July 29, 2026). dailymed.nlm.nih.gov
- Drugs@FDA: application 022505, Egrifta (approval history; original approval November 10, 2010). accessdata.fda.gov
- FDA: Egrifta label for the more concentrated formulation (revised 11/2018). accessdata.fda.gov
- FDA: supplement approval letter for Egrifta WR, BLA 022505/S-020 (signed March 25, 2025). accessdata.fda.gov
- FDA: List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020. fda.gov
- FDA: Notice to Compounders, changes that affect compounding as of March 23, 2020. fda.gov
- FDA: Compounding and the FDA, Questions and Answers (current as of September 16, 2025). fda.gov
- FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026). fda.gov
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of April 22, 2026). fda.gov
- Federal Register (HHS notice): draft enforcement discretion policy for 503A peptide compounding (October 30, 2026). govinfo.gov
- FDA warning letter: Peak Performance Peptides (August 24, 2026). fda.gov
- FDA warning letter: NuScience Peptides LLC (August 24, 2026). fda.gov
- FDA warning letter: Tailor Made Compounding LLC (April 1, 2020). fda.gov
- WADA: 2026 Prohibited List. wada-ama.org
- Falutz et al. 2007, NEJM (first phase 3 trial). pubmed.ncbi.nlm.nih.gov
- Falutz et al. 2008, AIDS (52-week extension). pubmed.ncbi.nlm.nih.gov
- Falutz et al. 2010, J Acquir Immune Defic Syndr (second phase 3 trial). pubmed.ncbi.nlm.nih.gov
- Falutz et al. 2010, J Clin Endocrinol Metab (pooled analysis). pubmed.ncbi.nlm.nih.gov
- Stanley et al. 2014, JAMA (visceral and liver fat). pubmed.ncbi.nlm.nih.gov
- Stanley et al. 2019, Lancet HIV (fatty liver in HIV). pubmed.ncbi.nlm.nih.gov
- Stanley et al. 2019, free author manuscript on PubMed Central. pmc.ncbi.nlm.nih.gov
- Makimura et al. 2012, J Clin Endocrinol Metab (abdominal obesity without HIV). pubmed.ncbi.nlm.nih.gov
- Baker et al. 2012, Arch Neurol (cognition in older adults). pubmed.ncbi.nlm.nih.gov
- Clemmons et al. 2017, PLoS One (type 2 diabetes). pubmed.ncbi.nlm.nih.gov
- Ellis et al. 2025, J Infect Dis (cognition in HIV). pubmed.ncbi.nlm.nih.gov
- Badran et al. 2026, Obes Res Clin Pract (meta-analysis). pubmed.ncbi.nlm.nih.gov
- Stewart et al. 2026, eNeurologicalSci (pilot trial on cognition). pubmed.ncbi.nlm.nih.gov
- Colpaert et al. 2026, Drug Test Anal (anti-doping detection in volunteers). pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT03150511: Johns Hopkins trial of tesamorelin after peripheral nerve injury (recruiting; record updated 9 November 2026). clinicaltrials.gov
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.